Comparison of rate of infection in patients with psoriasis treated with Secukinumab with other biologic agents (adalimumab, etanercept, infliximab, ustekinumab): a retrospective,cohort study

Trial Profile

Comparison of rate of infection in patients with psoriasis treated with Secukinumab with other biologic agents (adalimumab, etanercept, infliximab, ustekinumab): a retrospective,cohort study

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Jun 2017

At a glance

  • Drugs Secukinumab (Primary) ; Adalimumab; Etanercept; Infliximab; Ustekinumab
  • Indications Psoriasis
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top